350 Winter St. NE, Rm 410, P.O. Box 14480, Salem, OR 97309

503-378-4140

dfr.oregon.gov

Prescription Drug Prices public hearing agenda

Date/time:

Wednesday, Dec. 4, 2024, 10 a.m. to 12:30 p.m.

Location:

In person: Room 260 at 350 Winter St. NE, Salem OR 97301

Online: Zoom webinar http://dcbspage.org/RXDRUGPRICEHEARING2024.

Phone: 669-254-5252 (toll-free); ID: 160 927 3735.

Oregonians are encouraged to submit testimony on drug pricing, submit questions related to drug pricing, and suggest future hearing topics. Once the meeting starts, members of the public can sign up to give testimony using the signup sheet in room 260 or in the Zoom chat window or email rx.prices@dcbs.oregon.gov before the date of the hearing.

Facilitator

 Andrew Stolfi (he/him), Oregon insurance commissioner, Department of Consumer and Business Services director

Moderators

- Sen. Deb Patterson (she/her)
- Rep. Emerson Levy (she/her)
- Rep. Rob Nosse (he/him)

Agenda

Welcome and introductions - 10 to 10:10 a.m.

- Andrew Stolfi
- Ralph Magrish (he/him), Prescription Drug Affordability Board executive director, DFR

Program staff presentation - 10:10 to 10:40 a.m.

- Sofia Parra (she/her), program coordinator, Drug Price Transparency Program, DFR
 - Program information.
- Taran Heins (he/him), research analyst, DFR
 - Reporting highlights from the drug price transparency annual report from manufacturers, pharmacy benefit managers (PBMs), and insurers.
- Lily Sobolik (she/her), senior policy advisor, DFR
 - Legislative policy recommendations.

1

First public comment period – 10:40 to 10:50 a.m.

Sign up during the meeting to provide testimony or email rx.prices@dcbs.oregon.gov before the hearing.

First invited panel – 10:50 to 11:35 a.m.

Topic: Drug advertising – Who really pays for drug advertising and is what you see what you get?

- Michael DiStefano, PhD, assistant professor, Center for Pharmaceutical Outcomes
 Research, Univ. of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
- Sneha Dave (she/her), founder and executive director, Generation Patient
- Dharia McGrew (she/her), PhD.; director, state policy, PhRMA
- Gray Brokaw, OSPIRG High Value Health Care Campaign Associate

Second invited panel – 11:35 to 12:20 p.m.

Topic: Drug rebates – Why are rebates necessary and how do they help or harm the consumer? How do they affect what drugs are available?

- Mihir Patel (he/him), PharmD, chief pharmacy officer, Regence Blue Cross Blue Shield of Oregon
- Dharia McGrew (she/her), Ph.D.; director, state policy, PhRMA
- Tony Grillo (he/him), PharmD, vice president of financial analysis, Express Scripts
- Benjamin N. Rome (he/him), MD, MPH, assistant professor of medicine, Harvard Medical School and Brigham and Women's Hospital

Second public comment period – 12:20 p.m. until end of hearing

Sign up during the meeting to provide testimony or email rx.prices@dcbs.oregon.gov before the hearing.

Notes

Members of the public who want to provide testimony can sign up in room 260 or sign up in the Zoom chat or email rx.prices@dcbs.oregon.gov before the hearing. Questions and written testimony can be sent to rx.prices@dcbs.oregon.gov before or after the hearing.

Public hearing webpage: https://dfr.oregon.gov/drugtransparency/Pages/public-hearings.aspx. The presentations and testimony will be posted on our webpage soon after the hearing and the recording will be available by Dec. 20.